SECsense Logo

Sangamo Therapeutics, Inc. 8-K Report Summary - December 22, 2024 Insights

$SGMO
Form 8-K
Filed on: 2024-12-30
Source
Sangamo Therapeutics, Inc. 8-K Report Summary - December 22, 2024 Insights

Here are the key insights extracted from the provided financial report section:

  1. Filing Information:
  • Filing Type: 8-K (Current Report)
  • Filing Date: December 22, 2024
  1. Company Details:
  • Company Name: Sangamo Therapeutics, Inc.
  • State of Incorporation: Delaware (DE)
  • SEC CIK Number: 0001001233
  • SEC File Number: 000-30171
  • EIN: 68-0359556
  • Address: 501 Canal Blvd., Richmond, CA 94804
  • Phone Number: 510-970-6000
  1. Security Information:
  • Type of Security: Common Stock
  • Par Value: $0.01 per share
  • Ticker Symbol: SGMO
  • Exchange: NASDAQ
  1. Period Covered:
  • The report pertains to a single day, December 22, 2024.

Summary:

This section details an 8-K filing by Sangamo Therapeutics, Inc., on December 22, 2024. The company is incorporated in Delaware and trades on NASDAQ under the ticker SGMO. The report indicates a singular date for reporting, which typically signifies significant events or changes within the company. Further analysis would require information on the content of the 8-K filing to understand the events that prompted this report.